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Graphical abstract 
 
 
Highlights  
 
 We summarized microarray for metallothionein detection. 
 The fields of applications are mentioned. 
 The clinical biomarkers possibilities are discussed. 
 
 
Abstract 
Metallothioneins (MTs), low molecular mass cysteine-rich proteins, which are able to bind up 
to 20 monovalent and up to 7 divalent heavy metal ions are widely studied due to their 
functions in detoxification of metals, scavenging free radicals and cells protection against the 
oxidative stress. It was found that the loss of the protective effects of MT leads to an 
escalation of pathogenic processes and carcinogenesis. 
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The most extensive area is MTs expression for oncological applications, where the 
information about gene patterns is helpful for the identification biological function, resistance 
to drugs and creating the correct chemotherapy. In other medical applications the effect of 
oxidative stress to cell lines exposed to heavy metals and hydrogen peroxide is studied as well 
as influence of drugs and cytokines on MTs expression and MTs expression in the adipose 
tissue. The precise detection of low metallothionein concentrations and its isoforms is 
necessary to understand the connection between quantity and isoforms of MTs to size, 
localization and type of cancer. This information is necessary for well-timed therapy and 
increase the chance to survival. Microarray chips appear as good possibility for finding all 
information about expression of MTs genes and isoforms not only in cancer, but also in other 
diseases, especially diabetes, obesity, cardiovascular diseases, ageing, osteoporosis, 
psychiatric disorders and as the effects of toxic  drugs and pollutants, which is discussed in 
this review.  
 
 
List of abbreviations: HCC – hepatocellular carcinoma, HFD – high fat diet, MMP - matrix 
metalloproteinase, MT – metallothionein, MTF – metal transcription factor, MRE – metal 
responsive element, ROS – reactive oxygen species. 
 
Keywords: drug; gene expression; metallothionein; microarray; resistance; tumour diseases 
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1. Introduction 
1.1. Metallothioneins 
Metallothioneins (MTs) are a group of low molecular mass cysteine-rich proteins, which were 
isolated from horse kidney by Margoshes and Vallee in 1957 [1]. These proteins are able to 
bind up to 20 monovalent and up to 7 divalent heavy metal ions [2] and their main functions 
include metal ions detoxification of the organism [3] and scavenging free radicals to protect 
cells against oxidative stress [4]. It was found that the loss of the protective effects of MT 
leads to an escalation of pathogenic process (Fig. 1). Moreover, there is increasing number of 
papers aimed at describing the role of these proteins in anticancer therapy [5-10]. 
 
1.2. Isoforms of metallothioneins 
Generally, mammalian metallothioneins isoforms could be divided into four groups as MT-1, 
MT-2, MT-3 and MT-4 [11]. The expression and localization of individual MT isoforms vary 
at intracellular level (cytosol, nucleus, lysosomes, and mitochondria) and in individual tissues. 
In human, eight members of MT-1 (MT-1A, 1B, 1E, 1F, 1G, 1H, 1M, 1X) one member of 
MT-2A [12,13], MT-3 and MT-4 [14] have been discovered. These isoforms have differing 
rates of degradation and could be distributed in various ratios in individual tissues. The 
general physicochemical properties of MT isoforms are similar, however there is some 
specialisation of biological function [15]. The most widely expressed isoforms in the body are 
MT-1 and -2. These occur in tissues of kidney, liver, intestine and pancreas. MT-1A, E, X and 
MT-2A isoforms were found in normal prostate tissue [3]. MT-2A isoform is also connected 
 5 
 
with the proliferative activity of human prostate cancer cells [16] and breast cancer [17]. 
Besides, metallothionein 2A’s polymorphs were studied for their association with the risk for 
a variety of diseases such as prostate cancer, atherosclerosis, stroke and diabetes [3,18]. MT-3 
is found mainly in the brain, but it is expressed also in heart, kidney, and stomach in trace 
amounts [19]. MT-4 can be detected in epithelia and the maternal deciduae [20]. 
 
1.3. Metallothionein expression 
Metallothionein expression is induced by numerous factors such as stress hormones, 
cytokines, reactive oxygen species (ROS), radioactive and UV irradiation and exposition to 
metal ions [21]. The metallothionein expression follows after the binding of transcription 
factor MTF-1 (metal regulatory-transcription factor-1) to the regulatory part MRE (metal 
responsive element), which is localized at promotor of MT-1 gene. MTF-1 contains six Zn-
fingers and in the cell it is stored in inactive form coupled with its inhibitor MTI [22]. Metal 
ions come into the intracellular space, where they are bound to MTI and by this way MTF-1 is 
activated and is able to induct expression of MTs by the attaching to MRE [23]. After the 
transcription and translation the posttranslational modifications such as phosphorylation, 
glycosylation, deamination and oxidation become crucial [24]. Other heavy metals are also 
able to induce MTs transcription via MRE, however only Zn and Cd are able to activate MTF-
1 [25]. 
Higher level of MT was discovered in proliferating cells. This fact should be caused by the 
increased need for Zn and DNA protection against ROS species [26]. The study of 
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metallothionein expression at mRNA level shows the role of this protein in the cell protection 
to high zinc concentration [27]. MT can also control the activity of zinc fingers by 
competition about Zn. It was shown that regulating the availability of zinc the thionein/Zn-
MT conjugate pair modulates the DNA-binding activity of zinc finger transcription factors 
[28]. The feasibility of exchanging of Cd2+ bound to transcription factors to Zn2+ by MT 
thereby restoring the DNA-binding activity of transcription factors is an important event of 
metal detoxification [28]. Under physiological conditions, the role of metallothionein is zinc 
reservoir for zinc-dependent proteins. 
At the protein level, MT has been examined as a marker of cancer [29] and also of metals’ 
and toxic compounds’ intoxication [30,31]. For these purposes, numerous analytical and 
biochemical methods are used [32,33], whereas the electrochemical ones seem to be the most 
sensitive [33-35]. Nevertheless, the tissue distribution can be well detected by 
immunohistochemistry, which was based for performing meta-analysis of metallothionein as 
an immunohistochemical marker of cancer [36]. Based on the published data it can be 
concluded that MT could be considered as a marker of tumour diseases, however, 
combination of mRNA and protein levels is needed [37,38]. Therefore, we aimed our 
attention at summarization of MT mRNA determination. 
 
2. PCR and RT-PCR 
Genotyping of various MT forms can be performed by polymerase chain reaction (PCR)-
restriction fragment length polymorphism (RFLP) technique. Using this method Krześlak et 
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al. investigated three known single nucleotide polymorphisms (SNP) of MT2A gene in 
patients with breast cancer [39]. They found that the rs28366003 SNP of MT2A is positively 
associated with breast cancer. In an in vitro study it could be shown that MT-2A induces 
MMP-9 up-regulation through the activation of NFκB and Ap-1 signalling pathways, which 
can facilitate the migration and invasion of breast cancer cells [17]. Earlier, the same SNP had 
been shown to be linked with higher MT2A mRNA expression in prostate cancer tissue [3]. 
Gene expression is obviously analysed by quantitative (real-time) reverse transcription 
polymerase chain reaction (qRT-PCR). Comparative analysis of transcriptomes of non-
malignant bone and osteosarcoma revealed that members from metallothionein groups such as 
MT-1E, MT-1H, MT-1X, MT-2A, MT-1B, MT-1G and MT-1L were up-regulated in 
osteosarcoma samples [40]. Three isoforms, MT-1E, MT-1H and MT-1X were among the ten 
most highly up-regulated genes between malignant tissue and non-malignant bone. RT-PCR 
was used to validate the differential expression of MT-1E [40]. Szelachowska et al. studied 
the mRNA levels of MT-1F, MT-1X and MT-2A like an evaluation of the radiotherapy 
effects on expression of metallothionein isoforms in human rectal adenocarcinoma [41]. They 
found high expression of MT-1F followed by MT-1X and MT-2A in carcinoma cells. All 
studied isoforms had even higher expressions after radiotherapy, but the change was not 
statistically significant [41]. MT protein expression (MT1/2) was also evaluated. There was 
no correlation between mRNA and protein levels [41]. Fu et al. studied MT-1G expression in 
primary thyroid cancers by qRT-PCR [42]. Comparing malignant and non-malignant thyroid 
tissues the down-regulation of MT-1G could be detected in cancer cells. Cell cycle arrest and 
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apoptotic cell death were induced and the migration and invasion were inhibited in thyroid 
cancer cell lines transfected with MT1G supporting the tumour suppressor function of this 
gene [42].  Based on these studies, it clearly follows that the expression of MT isoforms is 
interesting; however, a clear picture of more than one isoform is crucial. For studying more 
isoforms simultaneously, microarray technology can be useful. Therefore, the summary of 
this method for MT isoforms detection follows. 
 
3. Microarray 
3.1. Introduction to microarray technology 
Microarray is a relatively new technology for detection and characterization of DNA. This 
high-throughput genome analysis can be applied for studying DNA-protein interaction, 
transcription analysis, detection and characterization of genetic variants [43] and 
environmental toxicology [44]. The summary of microarray analysis is shown in Fig. 2. The 
basic description of DNA microarray is a collection of microscopic DNA spots attached to a 
solid surface [43]. One spot contains picomole amount of a specific DNA probe. Probes can 
be a short section of a gene or other DNA element used for hybridization of cDNA or cRNA 
in the sample (target) under high-stringent conditions. The probes are synthesized and then 
attached via surface engineering to a solid surface by a covalent bond to a chemical matrix in 
common microarrays. The solid surface can be glass or a silicon chip, in which case they are 
colloquially known as an Affy chip when an Affymetrix chip is used. Other microarray 
platforms use microscopic beads, instead of the large solid support (such as Illumina). 
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Alternatively, microarrays can be constructed by the direct synthesis of oligonucleotide 
probes on solid surfaces. DNA arrays are different from other types of microarrays only in 
that they either measure DNA or use DNA as part of its detection system (http://www.gene-
chips.com/). Probe-target hybridization is usually detected and quantified by detection of 
fluorophore-, silver-, or chemiluminescence-labelled targets to determine relative abundance 
of nucleic acid sequences in the sample. Relatively new is the electrochemical detection of 
probe-target hybridization based on enzymatic labelling of the target sequence. Numerous 
commercial microarray platforms covering human or model animal genomes are 
commercially available. 
Tissue microarrays are based on multiple immunohistochemical detection of proteins in up to 
1000 tissue cores in diameter of 0.6 mm (Fig. 3). These tissue cores are inserted into a 
paraffin block in an array pattern. Sections from this block are cut using a microtome, placed 
on a microscopic slide and analysed by any method of histological analysis. Other variation is 
frozen tissue microarray, where the frozen tissue cores in diameter of 2 mm are embedded in 
an optimal cutting temperature block [45].   
The use of microarrays has several advantages over traditional methods of proteins and 
nucleic acids detection. Large number of the samples can be simultaneously analysed with 
commercially available genomic slides.  
Microarrays allow us to monitor global changes in gene and protein expression. The signal is 
detected, quantified, integrated and normalized with software and reflect the gene expression 
profile or molecular portrait of given biological sample. However, this molecular portrait is 
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determined by the number and type of probes spotted on a slide, thus in traditional 
microarrays, only molecules that are searched, can be found [46].  
Microarray studies are still limited by access and cost, especially for non-mainstream 
samples. Tissue samples usually represent a mixture of different cell types, thus the observed 
global changes in expression profiles reflect the entire cell types present in sample. In some 
types of sample, especially early stages of tumours there is often problem with low amount of 
tissue available. Nucleic acids and protein microarrays are destructive methods – the cells are 
disrupted and further processed. In DNA and RNA microarrays the quality of nucleic acids 
and amplification steps may lead to distortion of expression profiles. In protein microarrays 
there are no amplification methods available, thus a high requirement on detection step is 
taken and  low-abundant proteins may be misrepresented [47]. 
The described techniques have been widely used in many fields allowing quick analysis of 
multiple samples studying the expression of thousands genes in a small sample volume. 
Thereby, we are describing highly throughput type of analysis. For this reason microarrays are 
abundantly used for comparative genomes hybridization and expression profiling in different 
types of samples. This results in finding of candidate genes, whose expression needs to be 
confirmed by other methods, such as qPCR, Western blot or RNA silencing (Fig. 4). 
 
3.2. Microarray-based analysis for detection of metallothioneins 
The aim of this review is to summarize articles on using microarray for studying MT 
expression within the period from 2010 to 2014. According to our best knowledge, there have 
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been published 46 papers covering the topic of this review (Table 1). These were separated 
into oncological application, and other medical application. 
 
3.2.1. Oncological application 
The detection of metallothionein by microarray is spread in oncological studies. The 
information about gene patterns is helpful for the identification biological function, resistance 
to drugs and creating the correct chemotherapy protocol. The most studied are tumours of 
head and neck, prostate carcinoma, ovarian carcinoma, hepatic tumours and colorectal 
carcinoma. Except human samples and cell lines the animal cancer models and also the action 
of carcinogens and side effects of cytostatics have been explored. 
 
3.2.1.1 Head and neck tumours 
In head and neck tumours metallothioneins were studied in connection with resistance to 
chemotherapeutics. In tongue squamous cell carcinoma the mechanisms of drug resistance 
were studied using sensitive (Tca8113) and pingyangmycin-induced multidrug-resistant 
(Tca8113/PYM) cell lines [48]. The resistance to cisplatin, pirarubicin, paclitaxel, adriamycin 
and mitomycin was investigated. By cDNA microarray it was found that MT-2A, MT-1B and 
MT-1K are up-regulated in Tca8113/PYM and it seems that the resistance of the cell line 
could be related with MT-2A. In further microarray analysis using the same cell lines MT-1X 
has been shown as a mediator of a novel gene TCRP1 (tongue cancer resistance-associated 
protein) associated resistance to cisplatin [49].  
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3.2.1.2 Prostate and ovarian cancer 
Copper homeostasis disturbances are involved in development of prostate disorders. Bigagli 
et al. investigating the 24 h influence of Cu within the very low concentration range from  
10-17 to 10-6 M to a non-neoplastic adult human epithelial prostatic cell line RWPE-1 showed 
that transcriptional regulation of MT has an important role in the tight control of intracellular 
free Cu (II) levels [50]. Microarray data demonstrated concentration dependent changes in the 
expression of various MT isoforms. MT-1B, MT-1E, MT-1G and MT-1H were down-
regulated in the lowest concentrations of Cu and up-regulated between 10-14 and 10-6 M. 
MT1-M and MTF1 also was down-regulated at lower concentrations and up-regulated within 
the concentration range from 10-9 to 10-6 M. MT-1A and MT-2A were up-regulated at all 
concentration in Cu-treated cells compared to cells without treatment (control). 
Using a dog animal model transcriptome analysis of sequential biopsies representing the onset 
of benign prostatic hyperplasia has been performed to characterize the gene expression pattern 
associated with prostatic hyperplasia [51]. A number of genes involved in detoxification, cell 
movement, calcification, matrix remodelling, mucosa protection, transdifferentiation, 
senescence and apoptosis programs have been identified as altered, including MT-2A. Han et 
al. (2013) analysed MT-1H expression in 30 sets of microarray data of human malignancies 
[52]. A consistent down-regulation of MT-1H seems to be present in various types of 
malignant tumours compared with normal tissues. For further validation MT-1H in situ 
hybridization was performed on tissue microarray containing normal prostate tissues and 
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prostate cancer samples [52]. Significantly decreased MT-1H expression has been found in 
cancer tissues compared with normal prostate, and low level of expression in tumours was 
associated with poor clinical outcome. In vitro MT-1H has been shown to exert tumour 
suppressor effect on prostate cells via interacting with euchromatin histone methyltransferase 
1. 
In tissue microarray analysis of primary ovarian cancer samples the negative nuclear 
expression of metallothionein protein has been demonstrated to predict a better therapeutic 
response to adjuvant platinum-based chemotherapy and improved progression-free survival of 
patients [53]. 
 
3.2.1.3 Hepatic tumours 
Genes that could be used as markers of liver fluke-associated intrahepatic 
cholangiocarcinoma, were analysed by Subrungruang et al. [54]. More than 3 000 genes were 
found to be up- or down-regulated in cholangiocarcinoma tissues compared to normal liver 
tissue samples. Genes from metallothionein family (namely MT-1A, MT-1E, MT-1F, MT-1G, 
MT-1H, MT-1X and pseudogene MT1-IP) were down-regulated and showed significant 
changes in expression.  
Total RNA and genomic DNA were extracted from hepatocellular carcinoma (HCC) and non-
malignant liver tissue for gene expression profiling and SNP chip array analysis by Kanda et 
al. [55]. Double array analysis method with complementary qRT-PCR and methylation-
specific PCR (MSP) was suitable for identification of metallothionein 1G as tumour 
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suppressor gene and to show that it is silenced in HCC by promoter hypermethylation [55]. 
Later on, the expression of MT1/2 was evaluated immunohistochemically in tissue 
microarrays containing samples from HCCs, adjacent noncancerous livers, and normal livers 
[56]. This study demonstrated the loss of nuclear and cytoplasmic expression of MT1/2 in 
HCC compared with adjacent noncancerous liver tissues and that the loss of nuclear MT1/2 
expression is an independent prognostic indicator of poor recurrence-free survival and overall 
survival in patients with HCC [56]. 
Furthermore, the toxicity of cadmium was studied on human hepatoblastoma cells (HepG2) 
by the Agilent Whole Human Genome Oligo Microarray [57]. The cells were exposed to 2 
and 10 µM concentration of CdCl2 for 24 h. At the higher concentration a number of genes 
related to cancer development were up-regulated and many genes connected to liver function 
were down-regulated, whereas at the lower concentration the up-regulation of various 
metallothionein isoforms (MT-1A, MT-1B, MT-1E, MT-1F, MT-1G, MT-1H, MT-1J 
(pseudogene), MT-1M, MT-1L (gene/pseudogene), MT-1X, and MT-2A) was demonstrated 
as a protection mechanism against cadmium toxicity [57]. 
 
3.2.1.4 Colon cancer 
Microarray analysis of colon cancer samples and adjacent normal mucosa tissues from 40 
cancer patients, who had undergone tumour resection without receiving preoperative therapy, 
was performed [58]. Compared to normal tissues, the gene expression of MT-1F, MT-1G, 
MT-1X and MT-2A was down-regulated in colon cancer, which could be confirmed by qRT-
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PCR [58]. The tissue microarray analysis of samples demonstrated that MT1/2 protein 
expression was decreased in tissues with down-regulated MT mRNA expression. The results 
on protein expression were further confirmed by Western blot analysis [58]. Additional 
analysis of the loss of heterozygosity (LOH) and MSP showed that MT-1F is down-regulated 
mainly by LOH in colon cancer [58]. 
The influence of 50 µM rosiglitazone (PPARγ ligand) and 0.1 µM AS601245 (a selective 
JNK inhibitor) to human colon cancer cells (CaCo-2, HT29 and SW480) after 24 h treatment 
was studied [59]. It was found that rosiglitazone and AS601245 decrease cell adhesion and 
migration through modulation of gene expression. Because of similar effect of the treatment 
on all cell lines the microarray analysis was performed on CaCo-2 cell line only. After 
treatment with rosiglitazone the increased expression of genes coding for metallothioneins 
(MT-1X, MT-1E, MT-1G, MT-1H, MT-2A, MT-1M) was observed compared to untreated 
cell line. After combination with AS601245 metallothionein genes were still induced 
compared to untreated cells, but to a lesser extent than after treatment with rosiglitazone only 
[59].   
 
3.2.1.5 Other solid tumours 
Statistical analysis of the osteosarcoma transcriptomes from biopsy samples found differential 
expression of several metallothionein family members [40]. MT-1E, MT-1H, MT-1X, MT-
2A, MT-1B, MT-1G, and MT-1L, were up-regulated in osteosarcoma, and three (MT-1E, 
MT-1H and MT1-X) were among the 10 most highly up-regulated genes. Noteworthy, there 
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was no correlation between MT expression and chemoresistance in osteosarcoma [40]. In 
another study the gene expression of 73 high-grade soft tissue sarcoma samples was analysed 
by cDNA Microarray and clustered by complete-linkage hierarchical clustering [60]. The ratio 
of the gene expression in the sample relative to the average signal of expression of all genes 
examined was determined. Importantly, the samples of patients with the highest rate of 
metastases were characterized by MT-2A, MT-1X, MT-1F and MT-1H over-expression [60]. 
Scaruffi et al. investigated the transcriptome of resident bone marrow cells from localized and 
metastatic neuroblastoma patients compared to healthy subjects [61]. They found an altered 
gene expression in bone marrow cells including over-expression of metallothioneins. 
The biology behind ependymoma recurrence was also studied by expression microarray [62]. 
The expression of metallothioneins (MT-1L, MT-1G, MT-1E, MT-1X, MT-1B, MT-2A, and 
MT-3) was down-regulated in 65 to 85 % of relapses depending on the MT compared with 
initial tumours thereby representing a group of the most homogenously differentially 
expressed genes in recurrences. The neural growth inhibitory factor MT-3 was the most 
frequently down-regulated gene among metallothioneins, which was confirmed by qRT-PCR 
and immunohistochemistry [62]. In addition, tissue microarray analysis in an independent 
cohort of paediatric ependymomas demonstrated lower MT-3 protein expression at relapse 
compared to diagnosis in 70.8% of patients [62]. 
Using tissue microarray it was found that over-expression of MT1/2 is significantly more 
frequent in primary cutaneous malignant melanoma with haematogenous metastases [63].  
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3.2.1.6 Haematological malignancies 
Gene expression profile of human myeloid leukaemia cells K562, namely PU.1-knockdown 
K562 cells versus control and PU.1-overexpressing K562 cells versus control, was 
investigated by microarray analysis [64]. The interest was focused on PU.1-transcription 
factor for haematopoiesis, since down-regulation of PU.1 seems to be related to development 
of various haematological malignancies. It was found that MT-1G and MT-1A were distinctly 
induced in PU.1-knockdown K562 cells [64]. Furthermore, negative correlations of PU.1 
expression with the MT-1G and MT-1A expressions, respectively, could be confirmed by 
analysing leukemic bone marrow cells derived from AML patients [64].  
 
3.2.1.7 Carcinogens and anticancer drugs 
Changes in the human genome-wide transcriptome of H9 human embryonic stem cell (hESC) 
line due to the exposure to 1 Gy of gamma-radiation were detected at 2 and 16 h post-
irradiation [65]. This study showed the over-expression of many genes including 
metallothioneins (MT-1M, MT-1L, MT-1H and MT-1G) in irradiated hESC at 16 h post-
irradiation.  
The induction of MT isoforms in response to anticancer drugs e.g., doxorubicin has been 
reported [66]. Microarray analysis can also be used to identify the target genes of MT. The 
influence of MT against cardiotoxicity of doxorubicin was studied on wild type (MT+/+) mice 
in comparison with MT-1/2 null (MT-/-) mice [66]. Global gene expression profiles of cardiac 
cells from two genotype mice have been analysed on the 4th day after doxorubicin (15 mg/kg, 
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i.p.) or equal volume of saline administration. 381 characteristically MT-responsive genes 
such as map3k6, fos, ucp3, car3, and atf3 were identified in response to doxorubicin [66].  
 
3.2.2. Other medical application 
Expression of metallothioneins is generally associated with oxidative stress in obesity, 
cardiovascular diseases, diabetes, osteoporosis, vision, but also with hepatotoxic and 
nephrotoxic effects of heavy metals and drugs. The role of metallothioneins in ageing, and 
psychiatric disorders is studied, too. 
 
3.2.2.1 Obesity 
Metallothioneins are expressed and upregulated e.g., by glucocorticoids in human adipose 
tissue [67]. MT-1 and MT-2 were also identified as hepatic glucocorticoid-regulated target 
genes using whole genome gene expression microarray [68]. Interestingly, MT-1 and -2 
knockout mice are moderately obese suggesting the role of these proteins in the regulation of 
energy balance [67]. Cui et al. investigating spleen oxidative stress induced by high-fat diet 
(HFD) showed the down-regulation of MT-1 gene in the HFD (21.2% fat, w/w) mice 
compared with the controls (4.9% fat) [69]. In another study, male C57BL/6 mice were 
exposed to dietary restriction (75% of normal diet for 6 months) followed by 6 months of ad 
libitum refeeding. This group was compared with continuously ad libitum fed control group 
[70]. Dietary restriction resulted in lower body weight. Transcriptome analysis in mouse liver 
was done and 239 and 184 genes were at least two times up- or down-regulated in dietary 
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restriction compared to ad libitum fed control group [70]. MT-1 was increased in the group 
with dietary restriction.  
 
3.2.2.2 Cardiovascular diseases 
In the adult the protective and antioxidative effect of high density lipoprotein (HDL) on the 
vascular endothelium is assumed [71]. However, in a microarray study, investigating the 
effect of foetal HDL, which represents the main lipoprotein class in cord blood and is 
characterized by high proportion of apolipoprotein E, on human placental endothelial cells 
(HPEC) showed that foetal HDL reduced the MT1-X and MT-2A expression [71]. Foetal 
HDL is thought to exert key functions for development and metabolism of foetal tissues, and 
seems to be particularly important for the development of the central nervous system [71]. 
The effects of the apolipoprotein A1-rich adult HDL on MT synthesis might be different and 
still has to be determined. 
Cadmium is known to induce vascular diseases such as atherosclerosis. Toxicity of non-lethal 
dose of cadmium on human coronary artery endothelial cells (HCAEC) was studied by 
microarray utilizing of OpArrayTM Human V4.0 slide [72]. There were only 3 genes for 
which the levels of expression increased more than 2-fold, the MT-1E, MT-1H, and MT-1B, 
which underlines the importance of these MT isoforms in the vascular protection against 
heavy metal toxicity. 
Hyperbaric oxygen treatment (HBOT) seems to have beneficial effects on wound healing and 
reparative angiogenesis [73]. Global gene expression analysis on human microvascular 
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endothelial cells exposed to hyperbaric oxygen under conditions similar to a clinical treatment 
showed  that some metallothioneins especially MT-1E, MT-1F, MT-1G, MT-1H, MT-1M and 
MT-1X were up-regulated immediately after HBOT, some metallothioneins as MT-1E, MT-
1F, MT-1H and MT-1X after 24 h [73].  
 
3.2.2.3 Diabetes 
Pancreatic beta-cell dysfunction has a central role in the development and progression of type 
2 diabetes. Microarray analysis on beta-cells obtained from patients with diabetes of type 2 
revealed the significant up-regulation of MT-1E, MT-1M, MT-1X, MT-2A, and the 
pseudogene MT-1P2 [74]. This finding was assumed to reflect alterations in oxidative stress 
[74]. Nutrigenomics means the utilization of microarray technique to study the effects of 
nutrients and food compounds on gene expression thereby better understanding how the 
nutrients regulate biological processes [75]. Taurine (2-aminoethanesulfonic acid) seems to 
have a protecting effect against insulin resistance and diabetes mellitus [75]. Microarray 
analysis on human colon carcinoma derived Caco-2 cells showed the up-regulation of 
thioredoxin interacting protein (TXNIP) and MT-1H. Therefore, it was concluded that anti-
inflammatory and anti-oxidative effects of taurine may partly due to the increased MT-1H 
expression [75]. 
In the Nagaya-Shibata-Yasuda (NSY) mouse, which is an animal model of type 2 diabetes, 
high-sucrose diet increases the glucose intolerance, body weight gain, and induces liver 
steatosis [76]. Microarray analysis to detect hepatic gene expression levels revealed 
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significantly lower MT-1 and MT-2 expression in NSY mice compared with control C3H 
mice, irrespective of diet [76]. Considering the biological modulating activity of MT on liver 
mitochondria, down-regulation of MT was thought to contribute to the development of 
steatohepatitis and obesity [76]. Transcriptome analysis on liver has also been determined in 
C57BL/6J mice fed with a high-glucose diet for 4 weeks [77]. Elevated fatty acid 
accumulation in liver, insulin resistance at higher body weight have been observed with 
upregulation of 197 genes and down-regulation of 189 genes in liver [77]. The expression 
levels of MT-2 decreased compared to control. 
 
3.2.2.4 Hepatotoxicity 
Antioxidant and hypolipidaemic activities of a low concentration (300 μg/ml) of Tamarindus 
indica L. fruit pulp methanol extract was tested on human hepatoma HepG2 cell line [78]. 
Several genes that are related to reactive oxygen species and lipid metabolism showed 
changes in their expression. MT-1M, MT-1F and MT-1X were up-regulated, but not other 
MT isoforms [78]. 
Toxic effects of polychlorobiphenyls (PBC), namely coplanar PCB-77 and non-coplanar 
PCB-153 on HepG2 cells were studied by microarray analysis [79]. It was shown that both 
agents induce oxidative stress, but through involvement of different gene sets. PCB-77 
triggers the receptor mediated nuclear apoptotic pathway, whereas PCB-153 triggers the 
mitochondrial apoptotic pathway [79]. Interestingly, MT-1K, MT-1X and MT-1F were 
involved in the response to PCB-153, but not to PCB-77. 
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MT-1 and MT-2 are important protective factors against Cd toxicity, however, MT-3 null 
mice are resistant to Cd hepatotoxicity [80]. Microarray analysis on liver of MT-3 null and 
wild type mice at 4 hs after 20 μmol/kg Cd injection showed that only 37 genes were 
differentially expressed [80]. Cd induced up-regulation of the inflammation-associated 
cytokines serum amyloid A1 and A2 was inhibited in the liver of MT-3 null mice. There has 
not been altered expression of other MT isoforms [80]. 
 
3.2.2.5 Nephrotoxicity 
Using cDNA microarray to analyse global gene expressions of cortical renal tissue of mice 
immunized with cationic-bovine serum albumin to induce membranous 
glomerulonephropathy (MN) Wu et al. (2011) revealed 175 genes with significantly different 
expressions compared with normal kidneys [81]. They proposed that some of the 
differentially expressed genes might be used as biomarkers for human MN and should be 
tested on human samples. Significant up-regulation of MT-1 in association with MN was 
confirmed by qRT-PCR [81].  
 
3.2.2.6 Psychiatric disorders     
Shelton et al. investigated post-mortem brain tissue samples from 14 depressed persons who 
were psychotropic drug free at the time of death and age- and sex-matched normal controls 
[82]. Microarray analysis of Brodmann Area 10 tissue samples using the Affymetrix Exon 1.0 
ST arrays showed differential expression of genes that are related to inflammation, apoptosis 
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and oxidative stress. MT-1M expression was reduced in samples derived from patients with 
major depression as confirmed by qRT-PCR, which suggests an important role of this isoform 
in protection against local inflammation and development of depression [82].  
Gene expression changes associated with suicide in brains of mood disorder patients were 
studied by microarrays (Affymetrix HG-U133 Plus2.0) in the dorsolateral prefrontal cortex, in 
the anterior cingulate cortex and in nucleus accumbens [83]. Several MT-1 and MT-2 
isoforms (MT-1E, MT-1F, MT-1G, MT-1H, MT-1X, and MT-2A) were down-regulated in 
the anterior cingulate cortex of suicide subjects compared with non-suicides, and three of 
them (MT-1F, MT-1G, and MT-1H) were also down-regulated in the nucleus accumbens. 
MT-1M and MT-3 showed no differential expression between suicides and non-suicides [83]. 
It was concluded that failed neuroprotection against stress due to decreased expression levels 
of MT-1 and MT-2 might be molecular risk factor for suicide [83]. 
A mouse model consisting of two inbred mouse lines showing high (HAB) and low (LAB) 
anxiety-related behaviour can be used to analyze the traits of anxiety and depression [84]. In 
this model Czibere et al. investigated the gene expression in emotion-regulating parts of the 
limbic system and the brain regions closely connected to them using microarray [84]. More 
than 300 genes were differentially expressed between HAB and LAB mice in all analysed 
brain regions. Significantly lower MT-1 expression in HAB mice was confirmed by qRT-PCR 
[84]. 
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3.2.2.7 Ageing 
The protein levels of MT1/2 were studied in ageing skin by tissue microarray [85]. The 
expression of MT1/2 decreased significantly with increasing age, just like the expression of 
the proliferation markers Ki-67 and PCNA. The decline was more pronounced in sun-exposed 
skin [85]. 
 
3.2.2.8 Osteoporosis 
Genome-wide gene expression was analysed in primary cultures of osteoblasts derived from 
osteoporotic and non-osteoporotic human bone tissue samples [86]. The microarray data 
revealed that oxidative stress might be involved in the pathogenesis of osteoporosis. In further 
in vitro experiments the expression of MT-1G was confirmed to be important in response to 
oxidative stress in bone cells [86].  
 
3.2.2.9 Vision 
Whole-genome expression profiling of cornea, retinal pigment epithelium, trabecular 
meshwork, iris, lens, ciliary body, retina and sclera obtained from human cadaver eyes was 
examined focusing on MT expression [87]. MT-1A, MT-2A and MT-1X were highly 
expressed in all the tissues, but in particular in cornea, lens and iris. It might reflect that 
cornea and lens are natural barriers to external environmental insults e.g., UV radiation. MT-
1G was also highly expressed in lens. The expression levels of MT-1E, MT-1F, MT-1M and 
MT-1G were lower compared to MT-1A, MT-2A and MT-1X [87]. MT-1H and MT-3 
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isoforms were expressed at very low levels, whereas MT-1B and MT-4 expression was 
undetectable. Microarray analysis was also used to investigate MT gene expression in a 
human corneal epithelial cell line exposed to ZnSO4 [87]. MT-1 group, in particular MT-1B, -
1E, -1F, -1G, -1H, and -1X, were highly induced in corneal epithelial cells in the presence of 
zinc. 
Regional (superior-inferior) variations in gene expression in the retina of C57BL/6J mice 
exposed to hyperoxia for 14 days were examined using microarray technique [88]. Relatively 
few genes were differentially expressed between the inferior and superior retina in normoxic 
conditions, but many immune-, cell defence-, and inflammation-related genes were identified 
as differentially expressed in hyperoxic conditions, and higher number of genes showed 
altered expression in response to hyperoxia in the inferior retina, which is known to be more 
vulnerable to hyperoxia. The expression of MT-1 and MT-2 were also more elevated in the 
inferior retina reflecting more tissue damage [88]. 
It is known that susceptibility of various inbred strains of mice to age-related retinal 
degeneration (ageRD) is different due to genes present in quantitative trait loci (QTL) on 
chromosomes (Chr) 6, 10, 16, 14, 18, 12, 13, and 8 [89]. Genes that are differentially 
expressed between ageRD resistant and sensitive strains were examined by microarray, and 
then genes that are localized to the Chr 6 and Chr 10 QTL were further analysed. It was noted 
that, interestingly, the expression levels of MT-1 and MT-2 genes are higher in posterior 
eyecups of ageRD resistant mice comparing with sensitive ones suggesting a difference 
between the two strains in the capacity to respond to oxidative stress [89]. 
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3.2.2.10 Others 
To gain an insight into the pathogenesis of non-steroidal anti-inflammatory drug-induced 
small intestine injury, gene expression profiles in the intestinal mucosa of Wistar rats were 
investigated 24 hs after indomethacin administration [90]. It was found that MT-1A was 
down-regulated in the intestinal mucosa after application of indomethacin, but the treatment 
with rebamipide, which inhibited the small intestinal injury, could reverse the altered gene 
expression. 
Endotoxin tolerance means a reduced capacity of a mononuclear cell to respond to endotoxin 
(LPS) activation after an initial exposure to this stimulus, probably to protect tissues from 
hyperinflammation [91]. Gene responses in mononuclear cells during endotoxin tolerance 
were examined by microarray. It was shown that metallothioneins (MT-1H, MT-1F, MT-1A, 
MT-1X, MT-1E, and MT-2A) were strongly up-regulated in endotoxin tolerance [91]. 
 
4. Conclusions  
 
Metallothioneins could be considered as promising prognostic/predictive biomarkers of 
oncology diseases, but the changes in their expression were also found in diabetes, 
cardiovascular diseases, psychiatric disorders, vision impairments and others (Table 1). The 
precise detection of low metallothioneins concentrations and their isoforms is necessary for 
understanding the connection between the metallothioneins quantity and isoforms and size, 
localization and type of cancer. This information could be useful for well-timed therapy and 
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could thus increase the chance to survival. Microarray chip appears as good possibility for 
studying isoforms’ expression. In addition, microarrays allow investigating the gene 
expression differences and alterations in their network context thereby providing new data 
about functions and initiating biologically significant experimental studies. 
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Captions for Figures 
 
Figure 1 
Summary of MT functions in human diseases. 
 
Figure 2 
Comparison of different requested steps for various microarray detections. (A) Describes two 
cell populations (diseased and control sample), RNA extraction, cDNA preparation and 
labelling by Cy5 (red) or Cy3 (green) fluorochrome, purification, targeting and fluorescence 
detection. (B + C) Describe steps needed for microarray detected by electrochemistry, (B) 
diseased and (C) control sample. Microarray probes are hybridized to biotin-labelled targets. 
The HRP-streptavidin conjugate binds to biotin, and enzymatic oxidation of the electron 
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donor substrate then occurs. The approach is based on the detection of redox active 
chemistries (horseradish peroxidase (HRP) and the associated substrate 3,3’,5,5’–
tetramethylbenzidine (TMB)) proximal to specific microarray electrodes. The detection 
current is generated due to electro-reduction of the HRP reaction product. 
 
Figure 3 
Schematic illustration of tissue microarrays fabrication and processing. 
 
Figure 4 
Scheme of a microarray-based experiment. After cells treatment or tissues sampling, RNA is 
extracted and/or converted to cDNA and hybridized with immobilized probes. In case of 
tissue microarray, the tissue cores are embedded into a paraffin block, sliced using a 
microtome and subjected to multiple (immuno)histochemical staining. The up/down-regulated 
expression of candidate proteins is validated by independent techniques. 
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Table 1. Summary of MT isoforms detected by microarray in different samples. 
Abbreviations: a – ageing, cd – cardiovascular diseases, d – diabetes, dt – drug toxicity, h – 
hepatotoxicity, n – nephrotoxicity, o – obesity, os – osteoporosis , p – psychiatric disorders, t 
– tumour, vi – vision. 
 
Sample Analysed molecules Regulation of MT References Disease 
Cell 
cDNA 
MT-1B, MT-1K, MT-2A [48] t 
MT-1X [49] t 
RNA 
MT-1A, MT-1B,  MT-1E, MT-1G, MT-1H,  MT-1M,  MT-2A [50] t 
MT-1A,  MT-1B,  MT-1E,  MT-1F,  MT-1G, MT-1H,  MT-1J (pseudogene),  
MT-1M,  MT-1L (gene/pseudogene),  MT-1X,  MT-2A  [57] t 
MT-1E, MT-1G,  MT-1H,  MT-1M,  MT-1X,  MT-2A  [59] t 
MT-1B, MT-1E, MT-1G, MT-1H,  MT-1L,  MT-1X,  MT-2A [40] t 
MT-1G,  MT-2A  [64] t 
MT-1G,  MT-1H,  MT-1L, MT-1M [65] t 
MT-1E,  MT-1H,  MT-1X  [72] cd 
MT-1E, MT-1F, MT-1G, MT-1H,  MT-1M, MT-1X  [73] cd 
MT-1H  [75] d 
MT-1F, MT-1M, MT-1X  [78] h 
MT-1F,  MT-1G, MT-1X [79] h 
MT-1A,  MT-1E,   MT-1F, MT-1G,  MT-1X,  MT-2A [91] dt 
Tissue 
cDNA MT-1F,  MT-1H,  MT-1X, MT-2A   [60] t 
RNA 
MT-2A [51] t 
MT-1A, MT-1E,  MT-1F, MT-1G,  MT-1H, MT-1X,  pseudogene MT1-IP [54] t 
MT-1G [55] t 
MT-1F,  MT-1G, MT-1X,  MT-2A [58] t 
MT-1B, MT-1E, MT-1G,  MT-1H, MT-1L,  MT-1X,  MT-2A [40] t 
MT [61] t 
MT-1B,  MT-1E,  MT-1G,  MT-1L,  MT-1X,  MT-2A,  MT-3 [62] t 
381 characteristically MT-responsive genes [66] t 
MT-1, MT-2 
[68,69,76,88,8
9] o, o, d, vi, vi 
MT [92] o 
MT-1 [70,81,84] o, n, p 
MT-1X,  MT-2A  [71] cd 
MT-1E,  MT-1G,  MT-1M, MT-1X,  MT-2A [74] d 
MT-2  [77] d 
MT-3 [80] h 
MT-1M [82] p 
MT-1E,  MT-1F,  MT-1G,  MT-1H,  MT-1X, MT-2A [83] p 
MT-1G  [86] os 
MT-1A,  MT-1B,  MT-1E,  MT-1F,  MT-1G,  MT-1H, MT-1M,  MT-1X,  MT-
2A,  MT-3, MT-4 [87] vi 
MT-1A  [90] dt 
Tissue 
MT-1H [52] t 
MT-1 [53] t 
MT-1, MT-2 [56,63,85] t, t, a 
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